INOVIO PHARMACEUTICALS, INC. Stock-Based Compensation
INOVIO PHARMACEUTICALS, INC. (INO) reported Stock-Based Compensation of $1.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $768.44K, a 7.95% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $698.74K, a 50.07% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $764.56K, a 41.89% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $757.09K, a 38.94% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $3.76M, a 43.05% decline from fiscal 2024.
- INOVIO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $6.60M, a 40.44% decline from fiscal 2023.
- INOVIO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $11.07M, a 50.91% decline from fiscal 2022.
- INOVIO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $22.56M, a 14.36% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $768.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.47M 10-Q · filed 2026-08-12 | $2.23M derived: sum of 3 quarters · filed 2026-08-12 | $2.99M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $698.74K 10-Q · filed 2026-05-13 | $1.46M derived: sum of 2 quarters · filed 2026-05-13 | $2.22M derived: sum of 3 quarters · filed 2026-05-13 | $3.06M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $764.56K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.52M derived: sum of 2 quarters · filed 2026-03-12 | $2.36M derived: sum of 3 quarters · filed 2026-08-12 | $3.76M 10-K · filed 2026-03-12 |
| 2025-09-30 | $757.09K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.59M derived: sum of 2 quarters · filed 2026-08-12 | $2.99M 10-Q · filed 2025-11-10 | $4.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $834.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.23M 10-Q · filed 2026-08-12 | $3.55M derived: sum of 3 quarters · filed 2026-08-12 | $4.79M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.40M 10-Q · filed 2026-05-13 | $2.72M derived: sum of 2 quarters · filed 2026-05-13 | $3.95M derived: sum of 3 quarters · filed 2026-05-13 | $5.47M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.56M derived: sum of 2 quarters · filed 2026-03-12 | $4.07M derived: sum of 3 quarters · filed 2026-03-12 | $6.60M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.75M derived: sum of 2 quarters · filed 2025-11-10 | $5.28M 10-Q · filed 2025-11-10 | $7.55M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $4.04M 10-Q · filed 2025-08-12 | $6.31M derived: sum of 3 quarters · filed 2025-08-12 | $8.38M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.53M 10-Q · filed 2025-05-13 | $4.79M derived: sum of 2 quarters · filed 2025-05-13 | $6.87M derived: sum of 3 quarters · filed 2025-05-13 | $9.79M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $4.35M derived: sum of 2 quarters · filed 2025-03-18 | $7.26M derived: sum of 3 quarters · filed 2025-03-18 | $11.07M 10-K · filed 2025-03-18 |
| 2023-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $5.00M derived: sum of 2 quarters · filed 2024-11-14 | $8.81M 10-Q · filed 2024-11-14 | $12.08M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $6.73M 10-Q · filed 2024-08-08 | $10.00M derived: sum of 3 quarters · filed 2024-08-08 | $13.24M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.81M 10-Q · filed 2024-05-13 | $7.08M derived: sum of 2 quarters · filed 2024-05-13 | $10.32M derived: sum of 3 quarters · filed 2024-05-13 | $18.65M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $6.51M derived: sum of 2 quarters · filed 2024-03-06 | $14.84M derived: sum of 3 quarters · filed 2024-03-06 | $22.56M 10-K · filed 2024-03-06 |
| 2022-09-30 | $3.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $11.57M derived: sum of 2 quarters · filed 2023-11-09 | $19.28M 10-Q · filed 2023-11-09 | $24.76M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $8.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $16.05M 10-Q · filed 2023-08-09 | $21.52M derived: sum of 3 quarters · filed 2024-03-06 | $27.14M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $7.71M 10-Q · filed 2023-05-10 | $13.19M derived: sum of 2 quarters · filed 2024-03-06 | $18.81M derived: sum of 3 quarters · filed 2024-03-06 | $24.45M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $5.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $11.09M derived: sum of 2 quarters · filed 2024-03-06 | $16.74M derived: sum of 3 quarters · filed 2024-03-06 | $26.34M 10-K · filed 2024-03-06 |
| 2021-09-30 | $5.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $11.27M derived: sum of 2 quarters · filed 2022-11-08 | $20.86M 10-Q · filed 2022-11-08 | $24.69M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $5.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $15.24M 10-Q · filed 2022-08-09 | $19.07M derived: sum of 3 quarters · filed 2023-03-01 | $23.23M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $9.60M 10-Q · filed 2022-05-10 | $13.42M derived: sum of 2 quarters · filed 2023-03-01 | $17.58M derived: sum of 3 quarters · filed 2023-03-01 | $21.24M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $7.98M derived: sum of 2 quarters · filed 2023-03-01 | $11.65M derived: sum of 3 quarters · filed 2023-03-01 | $15.65M 10-K · filed 2023-03-01 |
| 2020-09-30 | $4.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $7.82M derived: sum of 2 quarters · filed 2021-11-09 | $11.82M 10-Q · filed 2021-11-09 | $13.86M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $3.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $7.66M 10-Q · filed 2021-08-09 | $9.70M derived: sum of 3 quarters · filed 2022-03-01 | $11.78M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $4.00M 10-Q · filed 2021-05-10 | $6.04M derived: sum of 2 quarters · filed 2022-03-01 | $8.11M derived: sum of 3 quarters · filed 2022-03-01 | $11.47M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $4.11M derived: sum of 2 quarters · filed 2022-03-01 | $7.47M derived: sum of 3 quarters · filed 2022-03-01 | $10.90M 10-K · filed 2022-03-01 |
| 2019-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $5.44M derived: sum of 2 quarters · filed 2020-11-09 | $8.87M 10-Q · filed 2020-11-09 | $11.01M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $6.79M 10-Q · filed 2020-08-10 | $8.93M derived: sum of 3 quarters · filed 2021-03-01 | $11.28M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $3.43M 10-Q · filed 2020-05-11 | $5.57M derived: sum of 2 quarters · filed 2021-03-01 | $7.92M derived: sum of 3 quarters · filed 2021-03-01 | $10.51M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $4.49M derived: sum of 2 quarters · filed 2021-03-01 | $7.08M derived: sum of 3 quarters · filed 2021-03-01 | $10.65M 10-K · filed 2021-03-01 |
| 2018-09-30 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $4.94M derived: sum of 2 quarters · filed 2019-11-12 | $8.52M 10-Q · filed 2019-11-12 | $11.19M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $2.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $6.16M 10-Q · filed 2019-08-08 | $8.84M derived: sum of 3 quarters · filed 2020-03-12 | $11.30M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $3.58M 10-Q · filed 2019-05-09 | $6.25M derived: sum of 2 quarters · filed 2020-03-12 | $8.71M derived: sum of 3 quarters · filed 2020-03-12 | $11.27M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $5.13M derived: sum of 2 quarters · filed 2020-03-12 | $7.70M derived: sum of 3 quarters · filed 2020-03-12 | $13.07M 10-K · filed 2020-03-12 |
| 2017-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $5.02M derived: sum of 2 quarters · filed 2018-11-08 | $10.39M 10-Q · filed 2018-11-08 | $13.49M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $7.94M 10-Q · filed 2018-08-07 | $11.03M derived: sum of 3 quarters · filed 2019-03-12 | $13.17M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $5.37M 10-Q · filed 2018-05-09 | $8.47M derived: sum of 2 quarters · filed 2019-03-12 | $10.60M derived: sum of 3 quarters · filed 2019-03-12 | $12.79M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $3.09M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $5.23M derived: sum of 2 quarters · filed 2019-03-12 | $7.42M derived: sum of 3 quarters · filed 2019-03-12 | $10.48M 10-K · filed 2019-03-12 |
| 2016-09-30 | $2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $4.33M derived: sum of 2 quarters · filed 2017-11-08 | $7.38M 10-Q · filed 2017-11-08 | $8.67M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $5.25M 10-Q · filed 2017-08-08 | $6.54M derived: sum of 3 quarters · filed 2018-03-14 | $7.66M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $3.06M 10-Q · filed 2017-05-10 | $4.34M derived: sum of 2 quarters · filed 2018-03-14 | $5.47M derived: sum of 3 quarters · filed 2018-03-14 | $6.83M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $2.41M derived: sum of 2 quarters · filed 2018-03-14 | $3.78M derived: sum of 3 quarters · filed 2018-03-14 | $6.19M 10-K · filed 2018-03-14 |
| 2015-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $2.49M derived: sum of 2 quarters · filed 2016-11-09 | $4.90M 10-Q · filed 2016-11-09 | $5.78M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $3.77M 10-Q · filed 2016-08-08 | $4.65M derived: sum of 3 quarters · filed 2017-03-15 | $5.45M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $2.41M 10-Q · filed 2016-05-09 | $3.29M derived: sum of 2 quarters · filed 2017-03-15 | $4.09M derived: sum of 3 quarters · filed 2017-03-15 | $5.32M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | $880.50K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $1.68M derived: sum of 2 quarters · filed 2017-03-15 | $2.91M derived: sum of 3 quarters · filed 2017-03-15 | $5.43M 10-K · filed 2017-03-15 |
| 2014-09-30 | $795.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $2.03M derived: sum of 2 quarters · filed 2015-11-09 | $4.55M 10-Q · filed 2015-11-09 | $5.08M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $3.75M 10-Q · filed 2015-08-10 | $4.28M derived: sum of 3 quarters · filed 2016-03-14 | $4.83M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | $2.52M 10-Q · filed 2015-05-11 | $3.05M derived: sum of 2 quarters · filed 2016-03-14 | $3.59M derived: sum of 3 quarters · filed 2016-03-14 | $3.87M derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | $529.92K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $1.07M derived: sum of 2 quarters · filed 2016-03-14 | $1.35M derived: sum of 3 quarters · filed 2016-03-14 | $1.87M 10-K · filed 2016-03-14 |
| 2013-09-30 | $544.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $819.21K derived: sum of 2 quarters · filed 2014-11-10 | $1.34M 10-Q · filed 2014-11-10 | $1.51M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-06-30 | $274.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $793.86K 10-Q · filed 2014-08-11 | $962.60K derived: sum of 3 quarters · filed 2015-03-16 | $1.22M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-03-31 | $519.22K 10-Q · filed 2014-05-12 | $687.96K derived: sum of 2 quarters · filed 2015-03-16 | $940.96K derived: sum of 3 quarters · filed 2015-03-16 | $1.21M derived: sum of 4 quarters · filed 2015-03-16 |
| 2012-12-31 | $168.74K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $421.74K derived: sum of 2 quarters · filed 2015-03-16 | $691.74K derived: sum of 3 quarters · filed 2015-03-16 | $1.35M 10-K · filed 2015-03-16 |
| 2012-09-30 | $253.00K 10-Q · filed 2012-11-07 | $523.00K derived: sum of 2 quarters · filed 2012-11-07 | $1.18M 10-Q · filed 2013-11-12 | $1.35M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $270.00K 10-Q · filed 2012-08-09 | $877.51K 10-Q · filed 2013-08-09 | $1.10M derived: sum of 3 quarters · filed 2014-03-17 | $1.36M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | $602.90K 10-Q · filed 2013-05-10 | $825.75K derived: sum of 2 quarters · filed 2014-03-17 | $1.09M derived: sum of 3 quarters · filed 2014-03-17 | $1.33M derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | $222.85K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $483.85K derived: sum of 2 quarters · filed 2014-03-17 | $731.85K derived: sum of 3 quarters · filed 2014-03-17 | $1.65M 10-K · filed 2014-03-17 |
| 2011-09-30 | $261.00K 10-Q · filed 2012-11-07 | $509.00K derived: sum of 2 quarters · filed 2012-11-07 | $1.43M 10-Q · filed 2012-11-07 | $1.69M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | $248.00K 10-Q · filed 2012-08-09 | $1.15M 10-Q · filed 2012-08-09 | $1.43M derived: sum of 3 quarters · filed 2013-03-18 | $1.80M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $981.16K 10-Q · filed 2012-05-09 | $1.18M derived: sum of 2 quarters · filed 2013-03-18 | $1.55M derived: sum of 3 quarters · filed 2013-03-18 | |
| 2010-12-31 | $200.76K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $572.40K derived: sum of 2 quarters · filed 2013-03-18 | $1.17M 10-K · filed 2013-03-18 | |
| 2010-09-30 | $371.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | $974.11K 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | $602.47K 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $2.16M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |